These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


915 related items for PubMed ID: 23668534

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E, Nigi L, Patti A, Fondelli C, Dotta F.
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF, Mannucci E, Ahrén B.
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
    Yasuda T, Shimomura I.
    Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
    [Abstract] [Full Text] [Related]

  • 7. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A.
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [Abstract] [Full Text] [Related]

  • 8. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.
    van Genugten RE, van Raalte DH, Diamant M.
    Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172
    [Abstract] [Full Text] [Related]

  • 9. Complementing insulin therapy to achieve glycemic control.
    Barnett AH.
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE, Salsali A.
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B, Schweizer A, Dejager S.
    Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J, Patterson S, O'Harte FP, Bell PM.
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [Abstract] [Full Text] [Related]

  • 15. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.
    Scheen AJ.
    Eur J Intern Med; 2012 Mar; 23(2):126-31. PubMed ID: 22284241
    [Abstract] [Full Text] [Related]

  • 16. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ.
    J Am Pharm Assoc (2003); 2009 Mar; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [Abstract] [Full Text] [Related]

  • 17. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B.
    Handb Exp Pharmacol; 2011 Mar; (203):53-74. PubMed ID: 21484567
    [Abstract] [Full Text] [Related]

  • 18. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK, Cobble ME, Reid TS, Shomali ME.
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell.
    Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL.
    Endocrinology; 2011 Dec; 152(12):4610-9. PubMed ID: 21971158
    [Abstract] [Full Text] [Related]

  • 20. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 46.